LY-01011 is under clinical development by Luye Pharma Group and currently in Phase III for Bone Metastasis. According to GlobalData, Phase III drugs for Bone Metastasis have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how LY-01011’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Denosumab biosimilar (LY-01011) is under development for the treatment of multiple myeloma, bone metastasis, giant cell tumor of bone and humoral hypercalcemia of malignancy. It is formulated as injection and administered through subcutaneous route. The drug candidate acts by targeting the receptor activator of nuclear factor kappa B ligand (RANKL).
Luye Pharma Group overview
Luye Pharma Group (Luye Pharma), a subsidiary of Luye Life Sciences Group Ltd, is a drug development company. It discovers, manufactures and commercializes novel formulations, generic drugs and pharmaceutical products. The company offers its products in the form of tablets, formulations for injections, capsules, gels, anti-psychotic medicines and modified-release dosages in the therapeutic areas of oncology, cardiovascular, orthopedics, hepatology, gastroenterology, gynecology, diabetes and central nervous system (CNS). Luye Pharma operates its research and development and manufacturing facilities in the US and China and, among others. Luye Pharma is headquartered in Yantai, Shandong, China.
For a complete picture of LY-01011’s drug-specific PTSR and LoA scores, buy the report here.